Remicade the main source of growth for Mitsubishi Tanabe
This article was originally published in Scrip
Executive Summary
Continued strong Japanese growth for Remicade (infliximab, licensed from Johnson & Johnson) helped offset other negative factors at Mitsubishi Tanabe Pharma (MTP) in the first half to September 30th, although overall sales at the company still fell.